Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10315915 | 1.00 | HRH3 (0.57) | HRH3KCNH2 | |
| SCHEMBL2475156 | 0.89 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2472661 | 0.89 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2479484 | 0.89 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2477768 | 0.89 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2474390 | 0.89 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL10315907 | 0.89 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2474741 | 0.89 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2521795 | 0.87 | HRH3 (0.73) | HRH3KCNH2 | |
| SCHEMBL2474463 | 0.86 | HRH3 (0.55) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373659-B1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-07-30 | — | — | EP | claimed |
| US-8217052-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-10 | — | — | US | claimed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | claimed |
| EP-2373659-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-12 | — | — | EP | claimed |
| WO-2010065798-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | claimed |
| EP-2373659-B1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-07-30 | — | — | EP | disclosed |
| US-8383814-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-8217052-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-10 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 1947/4885 |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.